Avenue Therapeutics (NASDAQ:ATXI) vs. Magenta Therapeutics (NASDAQ:MGTA) Head to Head Analysis – Tech Know Bits

Magenta Therapeutics (NASDAQ:MGTA) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, earnings, dividends, valuation and profitability.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Magenta Therapeutics and Avenue Therapeutics, as reported by MarketBeat.

Profitability

This table compares Magenta Therapeutics and Avenue Therapeutics net margins, return on equity and return on assets.

Insider & Institutional Ownership

63.4% of Magenta Therapeutics shares are owned by institutional investors. Comparatively, 8.7% of Avenue Therapeutics shares are owned by institutional investors. 10.9% of Magenta Therapeutics shares are owned by company insiders. Comparatively, 5.0% of Avenue Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk and Volatility

Magenta Therapeutics has a beta of 3.27, suggesting that its share price is 227% more volatile than the S&P 500. Comparatively, Avenue Therapeutics has a beta of -0.16, suggesting that its share price is 116% less volatile than the S&P 500.

Valuation & Earnings

This table compares Magenta Therapeutics and Avenue Therapeutics revenue, earnings per share (EPS) and valuation.

Avenue Therapeutics is trading at a lower price-to-earnings ratio than Magenta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Magenta Therapeutics beats Avenue Therapeutics on 7 of the 11 factors compared between the two stocks.

About Magenta Therapeutics

Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a novel stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent acute graft and host diseases. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

About Avenue Therapeutics

Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was founded in 2015 and is based in New York, New York.

Receive News & Ratings for Magenta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magenta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Read more:
Avenue Therapeutics (NASDAQ:ATXI) vs. Magenta Therapeutics (NASDAQ:MGTA) Head to Head Analysis - Tech Know Bits